Spectral Medical Gelecekteki Büyüme

Future kriter kontrolleri 1/6

Spectral Medical'in gelirinin yıllık 14.3% oranında artacağı tahmin edilmektedir. EPS'nin büyümesi yıllık 71.8% oranında artması beklenmektedir.

Anahtar bilgiler

n/a

Kazanç büyüme oranı

71.8%

EPS büyüme oranı

Biotechs kazanç büyümesi	32.8%
Gelir büyüme oranı	14.3%
Gelecekteki özkaynak getirisi	n/a
Analist kapsamı	Low
Son güncelleme	11 Nov 2024

Gelecekteki son büyüme güncellemeleri

Recent updates

We're Keeping An Eye On Spectral Medical's (TSE:EDT) Cash Burn Rate

Feb 12

Kazanç ve Gelir Büyüme Tahminleri

TSX:EDT - Analistlerin gelecek tahminleri ve geçmiş finansal verileri (CAD Millions )
Tarih	Gelir	Kazançlar	Serbest Nakit Akışı	Faaliyetlerden Nakit	Avg. Analist Sayısı
12/31/2025	2	N/A	N/A	N/A	1
12/31/2024	2	N/A	N/A	N/A	1
9/30/2024	2	-25	-9	-9	N/A
6/30/2024	2	-19	-9	-9	N/A
3/31/2024	2	-19	-9	-8	N/A
12/31/2023	2	-16	-11	-11	N/A
9/30/2023	2	-10	-11	-11	N/A
6/30/2023	2	-9	-10	-10	N/A
3/31/2023	2	-7	-11	-11	N/A
12/31/2022	2	-8	-10	-10	N/A
9/30/2022	2	-7	-10	-10	N/A
6/30/2022	1	-7	-10	-10	N/A
3/31/2022	2	-7	-10	-9	N/A
12/31/2021	2	-7	-9	-9	N/A
9/30/2021	2	-8	-9	-8	N/A
6/30/2021	2	-8	-9	-8	N/A
3/31/2021	2	-7	-8	-7	N/A
12/31/2020	2	-9	-1	0	N/A
9/30/2020	2	-8	-1	0	N/A
6/30/2020	2	-8	1	1	N/A
3/31/2020	3	-7	2	2	N/A
12/31/2019	3	-5	-3	-3	N/A
9/30/2019	4	-3	-2	-2	N/A
6/30/2019	4	-2	-2	-1	N/A
3/31/2019	3	-3	-2	-2	N/A
12/31/2018	4	-2	-2	-2	N/A
9/30/2018	3	-4	-3	-3	N/A
6/30/2018	3	-4	N/A	-3	N/A
3/31/2018	4	-4	N/A	-3	N/A
12/31/2017	4	-4	N/A	-4	N/A
9/30/2017	4	-4	N/A	-5	N/A
6/30/2017	4	-6	N/A	-7	N/A
3/31/2017	3	-8	N/A	-9	N/A
12/31/2016	4	-10	N/A	-11	N/A
9/30/2016	3	-11	N/A	-11	N/A
6/30/2016	3	-11	N/A	-10	N/A
3/31/2016	3	-10	N/A	-9	N/A
12/31/2015	3	-10	N/A	-9	N/A
9/30/2015	3	-10	N/A	-9	N/A
6/30/2015	3	-9	N/A	-9	N/A
3/31/2015	3	-9	N/A	-9	N/A
12/31/2014	3	-9	N/A	-10	N/A
9/30/2014	3	-11	N/A	-11	N/A
6/30/2014	3	-12	N/A	-10	N/A
3/31/2014	3	-12	N/A	-10	N/A
12/31/2013	3	-11	N/A	-9	N/A

Analist Gelecek Büyüme Tahminleri

Kazançlar ve Tasarruf Oranları: EDT 'un tahmini kazanç büyümesinin tasarruf oranının ( 2.3% ) üzerinde olup olmadığını belirlemek için yeterli veri yok.

Kazançlar ve Piyasa: EDT 'un kazançlarının Canadian pazarından daha hızlı büyümesinin öngörülüp öngörülmediğini belirlemek için yeterli veri yok

Yüksek Büyüme Kazançları: EDT şirketinin kazançlarının önümüzdeki 3 yıl içerisinde önemli ölçüde artıp artmayacağını belirlemek için yeterli veri bulunmuyor.

Gelir ve Pazar: EDT şirketinin gelirinin (yıllık 14.3% ) Canadian pazarından (yıllık 7% ) daha hızlı büyümesi öngörülüyor.

Yüksek Büyüme Geliri: EDT şirketinin gelirinin (yıllık 14.3% ) yıllık 20% oranından daha yavaş büyümesi öngörülüyor.

Hisse Başına Kazanç Büyüme Tahminleri

Gelecekteki Özkaynak Getirisi

Gelecekteki ROE: EDT 'un Özsermaye Getirisi'nin 3 yıl içinde yüksek olmasının öngörülüp öngörülmediğini belirlemek için yeterli veri yok

Spectral Medical Gelecekteki Büyüme

Future kriter kontrolleri 1/6

Anahtar bilgiler

Gelecekteki son büyüme güncellemeleri

Price target increased by 13% to CA$1.80

Consensus revenue estimates increase by 186%

Consensus revenue estimates decrease by 61%, EPS upgraded

No longer forecast to breakeven

Consensus forecasts updated

Consensus forecasts updated

Recent updates

Third quarter 2024 earnings released: CA$0.035 loss per share (vs CA$0.012 loss in 3Q 2023)

Spectral Medical Inc. Provides October Tigris Trial Update

Spectral Medical Inc. Provides September Tigris Trial Update

Independent Chairman of the Board recently sold CA$98k worth of stock

Spectral Medical Inc. Provides August Tigris Trial Update

Second quarter 2024 earnings released: CA$0.016 loss per share (vs CA$0.014 loss in 2Q 2023)

Spectral Medical Inc Provides July Tigris Trial Update

Spectral Medical Inc. announced that it has received $1 million in funding

Spectral Medical Inc. announced that it expects to receive $1 million in funding

Spectral Medical Inc. Provides June Tigris Trial Update

Independent Chairman of the Board exercised options to buy CA$102k worth of stock.

Spectral Medical Inc. announced that it has received CAD 8.499564 million in funding

First quarter 2024 earnings released: CA$0.015 loss per share (vs CA$0.006 loss in 1Q 2023)

Spectral Medical Inc. announced that it expects to receive CAD 8.499564 million in funding

Spectral Medical Inc. Provides Tigris Trial Update

Spectral Medical Provides Tigris Trial Update

Less than half of directors are independent

Price target increased by 13% to CA$1.80

Spectral Medical Inc. Announces Board Changes

Full year 2023 earnings: EPS and revenues miss analyst expectations

Spectral Medical Inc., Annual General Meeting, Jun 07, 2024

New minor risk - Market cap size

Spectral Medical Inc. Provides Update on the Company's Tigris Trial

Spectral Medical Announces Major Milestone by Reaching Its Interim Enrollment Target of 90 Patients

Spectral Medical Inc. Provides Early February Tigris Trial Update

Spectral Medical Provides January Tigris Trial Update

Spectral Medical Inc. l Enrolls Patient 82 in Its Phase 3 FDA Tigris Septic Shock Trial

Spectral Medical Inc. Provides November Tigris Trial Update

Spectral Medical Inc. Announces Executive Changes

Spectral Medical Inc. Announces Executive Changes

Spectral Medical Inc. Announces Publication of Tigris Trial Methods Paper

Third quarter 2023 earnings: EPS in line with analyst expectations despite revenue beat

Spectral Medical Provides Tigris Trial Update

New minor risk - Shareholder dilution

Spectral Medical Inc. announced that it has received CAD 6.217075 million in funding

Spectral Medical Inc. announced that it expects to receive CAD 5 million in funding from Paradigm Capital Inc.

Second quarter 2023 earnings released: CA$0.014 loss per share (vs CA$0.011 loss in 2Q 2022)

Spectral Medical Inc. Announces Tigris Clinical Trial Update

Spectral Medical Inc. Appoints David W. Feigal to Its Board of Directors

Spectral Medical Inc. Provides Update on Continued Favorable Tigris Clinical Trial Enrollment

Spectral Medical Inc. Provides Update on Favorable Tigris Clinical Trial Enrollment

Consensus revenue estimates increase by 186%

Consensus revenue estimates decrease by 61%, EPS upgraded

First quarter 2023 earnings: EPS in line with analyst expectations despite revenue beat

Spectral Medical Inc. Announces Resignation of Jim Funk as Director

No longer forecast to breakeven

Full year 2022 earnings: EPS and revenues exceed analyst expectations

Spectral Medical Inc. Provides Update on Tigris Clinical Trial

Consensus forecasts updated

Consensus forecasts updated

Price target decreased to CA$2.10

Forecast to breakeven in 2024

Spectral Medical Inc. announced that it has received CAD 6.8364 million in funding

Spectral Medical Inc. announced that it expects to receive CAD 8.5 million in funding

Spectral Medical Inc. announced that it expects to receive CAD 8.5 million in funding

Consensus forecasts updated

Second quarter 2022 earnings: EPS and revenues miss analyst expectations

Spectral Medical Provides Update on Tigris Clinical Trial

US FDA Grants Spectral Medical Breakthrough Device Designation for Toraymyxin™ for the Treatment of Endotoxemic Septic Shock

Spectral Medical Inc. Elects James Funk as Director

Spectral Medical Inc. Appoints Sam Amory as Dialco, President

First quarter 2022 earnings: EPS in line with expectations, revenues disappoint

Price target decreased to CA$2.10

Forecast breakeven date pushed back to 2024

Consensus revenue estimates fall by 44%

Spectral Medical Inc., Annual General Meeting, Jun 09, 2022

Spectral Medical Inc. Through Its Wholly-Owned Subsidiary Dialco Medical Inc. Provides Clinical Trial Update on Tigris, A Follow on Study Designed to Build on Knowledge Gained from the Earlier Euphrates Trial

We're Keeping An Eye On Spectral Medical's (TSE:EDT) Cash Burn Rate

Forecast to breakeven in 2023